Hydroxytyrosol and Olive Polyphenol Complex (EVOO): The Mediterranean Compound With an EFSA Claim

← Back to articles

The Mediterranean diet's cardioprotective effect has been hypothesized to depend on a few specific bioactive compounds in extra-virgin olive oil (EVOO) rather than on the diet's macro composition alone. The leading candidate is hydroxytyrosol — a small ortho-diphenolic compound and the most abundant phenolic in EVOO, along with its precursors tyrosol and oleuropein. These compounds together make up the broader "olive polyphenol complex" that appears in supplements as concentrated EVOO extracts. In 2011 the European Food Safety Authority approved a Article 13.5 health claim covering olive polyphenols at ≥5 mg of hydroxytyrosol + derivatives per day for "protection of LDL particles from oxidative damage" — making this one of the few supplement compounds with a regulatory-grade health claim.

The EUROLIVE Trial: The Foundational Evidence

The EUROLIVE multicenter crossover trial in 200 healthy male adults tested three olive oils (low, medium, high polyphenol content) at 25 mL daily for three weeks each. The high-polyphenol oil produced significant increases in HDL cholesterol, decreases in markers of LDL oxidation (oxidized LDL, plasma lipid peroxides), and improvements in the lipid risk profile in a dose-dependent manner. The trial established that EVOO's cardioprotective effect is meaningfully driven by its polyphenol content, not by its monounsaturated fat content alone. This is the primary evidence underpinning the EFSA claim.

The PREDIMED Context

The PREDIMED trial of 7,447 adults at high cardiovascular risk randomized to Mediterranean diet supplemented with EVOO, Mediterranean diet supplemented with mixed nuts, or low-fat control — and found a roughly 30% reduction in major cardiovascular events in the EVOO arm. The trial's results have been re-analyzed multiple times after methodological concerns, and the cardiovascular benefit has held up. PREDIMED used 50 g (4 tablespoons) of EVOO daily, which delivers approximately 30–50 mg of hydroxytyrosol and related polyphenols — well above the 5 mg EFSA threshold. See our heart health stack for the wider context.

The Supplement Form: Hydroxytyrosol Concentrates

Pure hydroxytyrosol is available as a supplement at 5–10 mg per capsule, often from olive leaf or olive mill wastewater extracts. The bioavailability is good — peak plasma concentration occurs within 1–2 hours and the compound is rapidly conjugated. The EFSA-grade claim is met by 5 mg daily of hydroxytyrosol and its derivatives (sum of hydroxytyrosol, tyrosol, oleuropein-aglycone). Whether the pure supplement reproduces the EVOO-matrix effect is debated — the polyphenol fraction in olive oil may have synergistic effects with the monounsaturated lipid matrix that pure isolates do not capture. Olive polyphenol complex products that mimic the EVOO compound ratio may be closer to the trial-validated form. See our pomegranate polyphenols comparison.

Other Indications: BP, Inflammation, Cognition

Beyond the EFSA-claimed LDL oxidation endpoint, hydroxytyrosol has emerging trial data for modest blood pressure reduction (~3–4 mmHg systolic) in pre-hypertensive adults, reductions in inflammatory markers (CRP, IL-6) in metabolic syndrome populations, and preliminary signals in cognitive aging. None of these are strong enough to anchor an individual indication, but they suggest the compound has effects beyond the lipid panel alone.

Dose, Form, and Practical Use

Two practical paths. (1) Consume 30–50 mL of high-polyphenol EVOO daily (look for "extra virgin" with polyphenol content ≥250 mg/kg on third-party-tested products) — this is the food-matrix path the PREDIMED data validates. (2) Supplement 5–10 mg hydroxytyrosol or 100–200 mg olive polyphenol complex daily — the regulatory-grade isolate path. Either is reasonable; the EVOO food path is preferred where dietary calories permit. See our hypertension and cholesterol condition pages.

Bottom Line

Hydroxytyrosol (and the broader olive polyphenol complex from EVOO) is one of the few supplement compounds with a regulatory-grade health claim plus large-RCT clinical outcome data behind it. Either via 4 tablespoons of high-polyphenol EVOO daily or via a 5–10 mg hydroxytyrosol capsule, it has a defensible place in evidence-based cardiovascular prevention.